Berita 24 English - Samsung BioLogics' shares rose as much as 5.2 per cent in early Monday trade following the company's agreement ...
Berita 24 English - Samsung BioLogics' shares rose as much as 5.2 per cent in early Monday trade following the company's agreement to fill-finish manufacture Moderna's COVID-19 vaccine.
The agreement was reached as part of a deal between Moderna Inc and Novavax Inc with the South Korean government to manufacture their COVID-19 vaccines.
As of 0007 GMT, the broad market was down 0.2 per cent.
